Management and Treatment of Paraneoplastic Syndromes

Pillar 1: Treatment of the Underlying Tumor

• Surgical resection, chemotherapy, or radiation directed at the primary tumor is the first priority.
• Many PNS improve or resolve with successful tumor treatment - for example, limbic encephalopathy often improves with tumor therapy, and acanthosis nigricans lesions often regress when the underlying malignancy is controlled (Goldman-Cecil Medicine, p. 1886-1888; Firestein & Kelley's Rheumatology).
• Paraneoplastic fever, night sweats, and cachexia resolve with successful tumor treatment; fever may herald relapse when it returns.

Pillar 2: Immunotherapy / Immunosuppression

• Antibodies against extracellular antigens (e.g., VGCC in Lambert-Eaton, VGKC, AMPA, NMDA-R): directly pathogenic, more responsive to immunotherapy.
• Antibodies against intracellular antigens (e.g., anti-Hu, anti-Ri, anti-Yo): T-cell mediated, less responsive to immunosuppression.

First-Line Immunotherapy Options

Second-Line / Steroid-Sparing Agents

• Azathioprine, mycophenolate mofetil, methotrexate (MTX): used in dermatomyositis, eosinophilic fasciitis, cancer-associated scleroderma.
• Cyclophosphamide: severe refractory cases.

Pillar 3: Symptomatic / Syndrome-Specific Treatment

A. Neurological PNS

B. Endocrine PNS

C. Rheumatologic PNS

D. Dermatologic PNS

• Paraneoplastic pemphigus (PNP): Rituximab (particularly in lymphoma-associated PNP), corticosteroids, IVIG, plasmapheresis, cyclosporine. Treat underlying malignancy (most often lymphoma, CLL, Castleman disease). Bronchiolitis obliterans - a devastating pulmonary complication - is difficult to treat. (Andrews' Diseases of the Skin)
• Bazex syndrome, erythema gyratum repens, acanthosis nigricans: treat underlying cancer; lesions may regress.
• Necrolytic migratory erythema (glucagonoma): somatostatin analogues (octreotide), tumor resection.

E. Hematologic PNS

• Paraneoplastic thrombosis (Trousseau syndrome): anticoagulation with low molecular weight heparin (preferred over warfarin in cancer-associated thrombosis).
• Anemia of chronic disease: treat underlying tumor; erythropoiesis-stimulating agents (ESAs) in selected patients.
• Pure red cell aplasia (thymoma): thymectomy; cyclosporine, corticosteroids.
• Disseminated intravascular coagulation: treat underlying malignancy; fresh frozen plasma, cryoprecipitate, platelet transfusion as needed.

F. Cachexia and Constitutional Symptoms

• Treat underlying tumor (primary intervention).
• Megestrol acetate (400-800 mg/day) improves appetite and weight, but causes fluid retention.
• Anamorelin (ghrelin receptor agonist, 100 mg orally once daily) improves lean body mass and appetite.
• NSAIDs or corticosteroids for paraneoplastic fever when tumor treatment is not possible.

Key Principles Summary

1. Tumor therapy first - the most important intervention; many PNS resolve with it.
2. Antibody type guides prognosis - extracellular antigen antibodies respond better to immunotherapy than intracellular antigen antibodies.
3. Steroids + IVIG + plasmapheresis are the backbone of acute immunotherapy; steroid-sparing agents for chronic management.
4. Syndrome-specific drugs (e.g., amifampridine for Lambert-Eaton, ketoconazole for ectopic Cushing, bisphosphonates for hypertrophic osteoarthropathy and hypercalcemia) are used in parallel.
5. Immune checkpoint inhibitor-associated PNS is a growing concern; a 2025 systematic review (Zhang et al., PMID 40042691) found antibody-positive PNS triggered by checkpoint inhibitors require cessation of the immunotherapy and aggressive immunosuppression.

Anamorelin

Drug Class and Mechanism

• Stimulates appetite and food intake
• Promotes lipogenesis and increases body weight
• Stimulates growth hormone (GH) secretion from the pituitary
• Raises IGF-1 and IGFBP-3 levels (anabolic axis)
• Improves gastric motility
• Has anti-inflammatory and anti-catabolic properties

Indication

Dosing

• 100 mg orally once daily, taken on an empty stomach (fasting state, at least 1 hour before the first meal)
• The 100 mg/day dose showed greater benefit than 50 mg/day in comparative analyses

Clinical Evidence

Key RCTs: ROMANA 1 & 2 (Phase 3, NSCLC)

• Anamorelin 100 mg/day vs. placebo in patients with advanced NSCLC and cachexia
• Results: Significant improvement in lean body mass and body weight but no significant improvement in handgrip strength (the co-primary endpoint)
• This failure on the functional endpoint led to non-approval in the US and EU

Phase 3: Japanese Trial (Katakami et al.)

• NSCLC + cachexia in Japanese patients
• Confirmed improvement in lean body mass, body weight, and appetite
• Led to Japanese approval (ONO-7643)

Meta-analysis (Rezaei et al., 2023 - PMID 37525932)

Network Meta-analysis (Chen et al., 2024 - PMID 39225556)

• Anamorelin 100 mg: +2.36 kg body weight vs. placebo
• Compared against olanzapine (+4.6 kg) and espindolol 20 mg (+3.82 kg)
• Anamorelin and olanzapine both useful for body weight improvement; superiority of olanzapine not confirmed by network meta-analysis

Pharmacodynamic Effects Summary

Adverse Effects

Limitations and Challenges

1. Handgrip strength / physical function: Consistently fails to improve in trials - the most clinically meaningful endpoint for cachexia.
2. Approval status: Approved in Japan; not approved by FDA or EMA as of current evidence (ROMANA trial results).
3. Monotherapy is insufficient: Cancer cachexia is multifactorial; anamorelin alone does not address inflammation, muscle protein breakdown, or functional decline fully.
4. Optimal patient selection: Evidence suggests earlier initiation (pre-cachexia or early cachexia stages) may yield better outcomes than late-stage use.

Current Role and Future Directions

• Best used as part of a multimodal approach combining:
  • Nutrition counseling (branched chain amino acids, omega-3 fatty acids)
  • Exercise / resistance training
  • Anti-inflammatory agents
  • Management of hormonal deficits (hypogonadism, vitamin D deficiency)
• Studies evaluating anamorelin in gastric, colorectal, and pancreatic cancers (beyond NSCLC) are ongoing.
• Goldman-Cecil Medicine recommends anamorelin (100 mg orally once daily) as providing "a favorable clinical response, including a significant increase in lean body mass" for cancer cachexia.

Summary